How COVID-19 Is Driving RWE Uptake In Clinical Trials
With the COVID-19 pandemic exacerbating the challenges of recruiting patients for studies targeting catastrophic diseases and rare cancers, regulators are becoming more receptive to new ways of using real-world evidence in clinical trials.
You may also be interested in...
A new evaluation route that the European Medicines Agency launched last year came at the right time for Takeda’s dengue vaccine candidate.
Executive Summary: The European pharma industry federation believes the advice provided in the updated draft EU guideline on additional risk minimization measures is far too detailed, resulting in a lack of focus, information overlap and confusion.
At its latest meeting in June, the International Council for Harmonisation agreed on new topics that could benefit from harmonized advice and took note of progress made on drafting and finalizing quality, safety and multidisciplinary guidelines.